RBC Capital Markets acted as exclusive financial advisor to E-Z-EM, Inc. in its sale to Bracco Diagnostics, Inc. and provided a fairness opinion

Transaction Information On April 1, 2008, Bracco Diagnostics, Inc. ("Bracco"), a subsidiary of Bracco Imaging S.p.A. announced that it had completed the acquisition of E-Z-EM, Inc. ("E-Z-EM") for cash consideration of $21.00 per share. Total consideration to E-Z-EM shareholders was $241.4 million. RBC Capital Markets acted as Exclusive Financial Advisor and provided a fairness opinion to E-Z-EM's Board of Directors. About E-Z-EM E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company is the developer of VoLumen®, a patent-pending, next generation low density barium sulfate suspension for use as an oral contrast in Multidetector CT (MDCT) and Positron Emission Tomography (PET/CT) studies. The Company also offers Empower®, the first family of CT injectors on the market with patented EDAT technology that can help detect contrast extravasation, and offers a complete product set for the virtual colonoscopy

practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and owel cleaners, tagging agents and a carbon dioxide colon insufflation system. The Company is also the exclusive world-wide manufacturer and marketer of RSDL for military services and first-responder organizations. RSDL is a patented, broad-spectrum liquid chemical warfare agent decontaminant, that neutralizes or removes chemical agents from skin on contact, leaving a non-toxic residue that can be rinsed off with water.

Investment Banking Contacts

Kevin Davies

Co-Head, U.S. Healthcare

212-428-6617

kevin.davies@rbccm.com

Michael Stroup

Director

415-633-8557

michael.stroup@rbccm.com